NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

They were looking for predictive factors in that retrospective, it was verified with observation, the latter is what the phase III trial relies upon to distinguish most, not all psPD, when they can't distinguish with the time given, 8-10 weeks post initial radiotherapy protocol, then they are either classified ePD or potentially ePD. The others are classified psPD and placed into the trial. The point is, that in your study, the scientists are looking for an indicator that tells them right off the bat (immediate end of first round of radiotherapy) which ones are psPD. That is not yet fully achievable.